Description
Product details
VILDIABATE M 850 Metformin (850mg)SR, Vildagliptin (50mg) Introduction Effective management of Type 2 diabetes requires treatments that are not only effective in controlling blood glucose levels but also favorable in terms of side effects and patient adherence. VILDIABATE M 850, combining Metformin SR (850mg) with Vildagliptin (50mg), offers a potent and balanced approach to diabetes care. This article explores how this combination therapy works, its benefits, and the advantages it brings to patients dealing with Type 2 diabetes. Understanding the Components of VILDIABATE M 850 Metformin SR (850mg) Metformin is a first-line medication in the management of Type 2 diabetes, known for its ability to reduce glucose production in the liver and improve insulin sensitivity in muscle and adipose tissues. The sustained-release (SR) formulation of 850mg allows for gradual release of the drug, which helps in maintaining steady blood glucose levels while minimizing gastrointestinal side effects commonly associated with higher doses of standard Metformin. Vildagliptin (50mg) Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the body’s natural ability to control high blood sugar by increasing the levels of incretin hormones. These hormones regulate glucose by increasing insulin release and decreasing glucagon secretion when needed, particularly after eating. This helps to control postprandial (post-meal) blood glucose spikes effectively. Synergistic Benefits for Diabetes Management Comprehensive Glycemic Control VILDIABATE M 850 effectively targets both fasting and postprandial blood glucose levels. Metformin works primarily on reducing fasting glucose levels, while Vildagliptin manages post-meal spikes. This dual-action approach helps in achieving better overall glycemic control, which is crucial for reducing the risk of diabetes-related complications over time. Reduced Risk of Hypoglycemia The combination of Metformin and Vildagliptin is associated with a low risk of hypoglycemia. Unlike other diabetes treatments that may excessively stimulate insulin production, Vildagliptin enhances the body’s natural insulin response in a glucose-dependent manner, which prevents the unnecessary lowering of blood glucose levels. Positive Impact on Weight Management Metformin has been known to aid in weight loss or maintenance, which is an essential aspect of managing Type 2 diabetes. Vildagliptin is also weight-neutral, ensuring that VILDIABATE M 850 does not contribute to weight gain, making it an excellent option for patients concerned about their weight. Ideal Candidates for VILDIABATE M 850 VILDIABATE M 850 is particularly suitable for individuals with Type 2 diabetes who: Have not achieved optimal glycemic control with other therapies. Require a robust regimen to manage both fasting and postprandial glucose levels. Are looking for a diabetes treatment with minimal risks of hypoglycemia. Need a medication that aligns with weight management goals. Dosage and Administration VILDIABATE M 850 is typically prescribed as one tablet taken once or twice daily, depending on the individual's specific needs and glycemic targets. Taking this medication with meals can help optimize Metformin absorption and reduce potential gastrointestinal side effects. Potential Side Effects While VILDIABATE M 850 is generally well tolerated, some patients may experience side effects such as: Gastrointestinal issues (less severe with the SR formulation). Headache or common cold symptoms associated with Vildagliptin. Regular monitoring and communication with a healthcare provider are essential to manage any side effects and adjust the treatment as necessary. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/vildiabate-m-850-133455
